In the ZENITH trial, Winrevair was evaluated based on a composite endpoint of all-cause death, lung transplantation or disease-related hospitalization for patients with pulmonary arterial hypertension ...

BofA lowered the firm’s price target on United Therapeutics (UTHR) to $314 from $328 and keeps an Underperform rating on the shares. The firm ...

We continue to have our sights set on fulfilling our promise to provide physicians and patients with what we believe can be a much-needed therapeutic alternative, and potentially the prostacyclin of ...

Building on our progress this past year, Liquidia has strengthened its financial position, with up to an additional $100 million available pursuant to an amendment to its existing financing agreement ...

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System ...

It is well acknowledged that metabolic disorder binds closely with preeclampsia, though some of the causal relationships are still ambiguous. This review systematically summarizes the metabolic ...

Background Pulmonary hypertension (PHT) lacks community prevalence and outcome data. Objective To characterise minimum ‘indicative’ prevalences and mortality data for all forms of PHT in a selected ...

MannKind’s stock has fluctuated due to Tyvaso DPI’s Q4 underperformance and competitive pressures, but it remains a key revenue driver for future profitability and R&D funding. Tyvaso DPI’s ...

And that's not all. We're tremendously excited for the potential of Ralinepag to be the first true once-a-day oral prostacyclin agonist for pulmonary arterial hypertension patients. If successful ...

Triple therapy for PAH pulmonary vasodilator treatment target 3 potent mediators of vascular tone: nitric oxide, prostacyclin and endotelin pathway. The prostacyclin metabolic pathway is dysregulated ...